Learn more

CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH

Overview
  • Total Patents
    13
  • GoodIP Patent Rank
    129,820
  • Filing trend
    0.0%
About

CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH has a total of 13 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2015. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and Mexico. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are IMMPORT THERAPEUTICS INC, CELCUITY INC and CEMM FORSCHUNGSZENTRUM FUR MOLEKULARE MEDIZIN GMBH.

Patent filings in countries

World map showing CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBHs patent filings in countries

Patent filings per year

Chart showing CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBHs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Superti-Furga Giulio 4
#2 Huber Kilian 4
#3 Kubicek Stefan 3
#4 Vladimer Gregory 2
#5 Licciardello Marco 2
#6 Snijder Berend 2
#7 Vladimer Gregory Ian 1
#8 Stefan Kubicek 1
#9 Jin Li 1
#10 Krall Nikolaus 1

Latest patents

Publication Filing date Title
EP3285753A1 Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
WO2016135138A1 Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
EP3227341A1 Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
US2017356911A1 Monolayer of pbmcs or bone-marrow cells and uses thereof
EP3143143A1 Antagonists of slc38a9 and their use in therapy